Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza

Stock Information for Cidara Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cidara Therapeutics Inc.

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.